Presence of calreticulin mutations in JAK2-negative polycythemia vera

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003 · see citing works

Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>

Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756 · see citing works

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Tefferi, A., Guglielmelli, P., Larson, D. R., Finke, C. M., Wassie, E. A., Pieri, L., Gangat, N., Fjerza, R., Belachew, A. A., Lasho, T. L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-579136 · Cited by 748 · see citing works

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

Lundberg, P., Karow, A., Nienhold, R., Looser, R., Hao-Shen, H., Nissen, I., Girsberger, S., Lehmann, T., Passweg, J. R., Stern, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-537167 · Cited by 632 · see citing works

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

Tefferi, A., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R. P., Hanson, C., Maffioli, M., Caramazza, D., Passamonti, F., & Pardanani, A. D. (2014) · Leukemia · doi:10.1038/leu.2014.3 · Cited by 547 · see citing works

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

Lippert, É., Boissinot, M., Královics, R., et al. (2006) · Blood · doi:10.1182/blood-2006-01-013540 · Cited by 235 · see citing works

Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms

Cross, N. C. P. (2011) · Hematology · doi:10.1182/asheducation-2011.1.208 · Cited by 120 · see citing works

Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis

Boyd, E. M., Bench, A. J., Goday‐Fernández, A., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08083.x · Cited by 106 · see citing works

An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia

Johansson, P. L., Safai‐Kutti, S., & Kutti, J. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05517.x · Cited by 103 · see citing works

Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia

Cassinat, B., Verger, E., & Kiladjian, J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1401255 · Cited by 76 · see citing works

JAK 2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort

McGaffin, G., Harper, K., Stirling, D., & McLintock, L. A. (2014) · British Journal of Haematology · doi:10.1111/bjh.12969 · Cited by 64 · see citing works

Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia

Álvarez‐Larrán, A., Ancochea, A., Angona, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.067348 · Cited by 61 · see citing works

Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis

Broséus, J., Lippert, É., Harutyunyan, A. S., Jeromin, S., Zipperer, E., Florensa, L., Feenstra, J. D. M., Haferlach, T., Germing, U., Luño, E., et al. (2014) · Leukemia · doi:10.1038/leu.2014.49 · Cited by 55 · see citing works

Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?

Cassinat, B., Laguillier, C., Gardin, C., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404908 · Cited by 50 · see citing works

Nested High-Resolution Melting Curve Analysis

Carillo, S., Henry, L., Lippert, É., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.12.002 · Cited by 30 · see citing works

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126 · see citing works

PB0742 JAK2 V617F Allele Burden and Thrombotic Events in Patients with JAK2 V617F Positive Polycythemia Vera or Essential Thrombocythemia at High Risk of Thrombosis

Bae, S., Hwang, Y.-H., Lee, A., et al. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.101322

[JAK2 V617F positive mutation transformed to calreticulin mutation in one patient with essential thrombocythemia].

Wang, S. Y., Zhang, L. J., Liu, Y. X., et al. (2017) · PubMed · doi:10.3760/cma.j.issn.0253-2727.2017.01.008

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status

Finazzi, G., Rambaldi, A., Guerini, V., et al. (2007) · Haematologica · doi:10.3324/haematol.10634 · Cited by 142 · see citing works

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia

Antonioli, E., Carobbio, A., Pieri, L., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.021444 · Cited by 50 · see citing works

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders

Basquiera, A. L., Soria, N. W., Ryser, R., et al. (2009) · Hematology · doi:10.1179/102453309x12473408860226 · Cited by 35 · see citing works